Melanocytic Neoplasm

To identify novel molecular mechanism(s) of resistance, we generated PLX4032-resistant cell lines by chronic exposure of the BRAF (V600E)-positive parental melanoma cell line Mel-CV to PLX4032. After … (full text at CIViC)

PMID 24201813 · Hu et al., 2013 · Open in CIViC

A 42 year old male patient with stage III cutaneous melanoma harboring an AGAP3::BRAF fusion was treated with the MEK inhibitor trametinib after prior pembrolizumab and experienced a response lasting … (full text at CIViC)

PMID 35871080 · Moran et al., 2022 · Open in CIViC

A patient with metastatic melanoma of unknown primary harboring an AGK-BRAF fusion with an intact BRAF kinase domain received belvarafenib 450 mg twice daily after progression on pembrolizumab, dacarb… (full text at CIViC)

PMID 38470950 · Kim et al., 2024 · Open in CIViC

BRAF fusion AGK-BRAF was associated with decreased sensitivity to vemurafenib and increased sensitivity to sorafenib in-vitro. A single patient with this fusion showed durable response to sorafenib.

PMID 23890088 · Botton et al., 2013 · Open in CIViC

In an in vitro study, a M229 cell line endogenously expressing BRAF V600E mutation (a known vemurafenib sensitizing mutation) and overexpressing AKT1 E17K mutation was associated with resistance to ve… (full text at CIViC)

PMID 24265155 · Shi et al., 2014 · Open in CIViC

A melanoma cell line (M262) with AKT E17K mutation was found to be sensitive to AKT inhibition with GSK2141795B in this study.

PMID 24735930 · Lassen et al., 2014 · Open in CIViC

A BRAF V600E-positive melanoma cell line (M262) with AKT E17K mutation was found to have a similar level of sensitivity to combination dabrafenib plus AKT inhibitor GSK2141795B (IC50 < 1nM) as to dabr… (full text at CIViC)

PMID 24735930 · Lassen et al., 2014 · Open in CIViC

An in vitro study of M229 (a human melanoma cell line) endogenously expressing wild-type AKT1 and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells induced to stably over-expre… (full text at CIViC)

PMID 24265155 · Shi et al., 2014 · Open in CIViC

In a retrospective study of 44 relapsed melanoma patients with BRAF V600E/K (known BRAF inhibitor sensitizing mutations), AKT1 Q79K was associated with acquired resistance to BRAF inhibitor (dabrafeni… (full text at CIViC)

PMID 24265155 · Shi et al., 2014 · Open in CIViC

The AKT1 Q79K mutation has been shown to confer resistance to BRAF inhibitors (vemurafenib) in melanoma cell line M229.

PMID 24265152 · Shi et al., 2014 · Open in CIViC

In an in vitro study, a M229 cell line endogenously expressing BRAF V600E mutation (a known vemurafenib sensitizing mutation) and overexpressing AKT1 Q79K mutation was associated with resistance to ve…

An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype AKT3 and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably ove… (full text at CIViC)

PMID 24265155 · Shi et al., 2014 · Open in CIViC

An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype AKT3 and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells induced to stably over-expres… (full text at CIViC)

PMID 24265155 · Shi et al., 2014 · Open in CIViC

Expression of an alternative ALK transcript (ATI), encompassing exons 20–29 preceded by ~400 base pairs (bp) of intron 19, but not exons 1–19 was identified in three samples of thyroid cancer and mela… (full text at CIViC)

PMID 26444240 · Wiesner et al., 2015 · Open in CIViC

Melanoma cell lines and xenografts expressing the ALK ATI variant did not respond to treatment with ALK inhibitors, while fusion ALK expressing cell lines and xenografts were sensitive.

PMID 29054983 · Couts et al., 2018 · Open in CIViC

In a case report of a patient with metastatic melanoma harhouring an in-frame ANO10-RAF1 fusion, a MEK inhibitor (trametinib) treatment resulted in brief, but significant, tumor regression and symptom… (full text at CIViC)

PMID 35135096 · Kim et al., 2018 · Open in CIViC

Melanoma cell lines were shown to have increased sensitivity to Temozolomide when siRNA-induced ATM knockdown was applied.

PMID 23960094 · Eich et al., 2013 · Open in CIViC

ATXN1L expression was analyzed in 30 BRAF V600-mutant untreated melanoma metastes. 21 of these patients were subsequently treated with dabrafenib or vemurafenib, and 9 of these patients were treated w… (full text at CIViC)

PMID 28178529 · Wang et al., 2017 · Open in CIViC

Whole exome sequencing (WES) was performed on 49 longitudinal tumour samples from 17 patients with metastatic melanoma, of whom 10 responded to ICIs/CPB, where 5 had durable responses, while 5 eventua… (full text at CIViC)

PMID 29070816 · Sade-Feldman et al., 2017 · Open in CIViC

Paired tumor samples were analyzed from four patients with metastatic melanoma and initial response with a subsequent relapse under pembrolizumab (PD-1 checkpoint inhibitor) therapy. Baseline biopsies… (full text at CIViC)

PMID 27433843 · Zaretsky et al., 2016 · Open in CIViC

In patients with uveal melanoma, those with BAP1 expression (determined by immunohistochemical staining) had better survival.

PMID 25147369 · van Essen et al., 2014 · Open in CIViC

Somatic and germline BAP1 mutations are associated with uveal melanoma. In this preclinical study, gene set enrichment analysis revealed HDAC inhibitors as potential drugs in BAP1 mutant uveal melanom… (full text at CIViC)

PMID 22038994 · Landreville et al., 2012 · Open in CIViC

In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated wi… (full text at CIViC)

PMID 31580757 · Menzer et al., 2019 · Open in CIViC

In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E or V600K (known BRAF inhibitor sensitizing mutations), MAPK pathway reactivation mechanisms were implicated in acquired r… (full text at CIViC)

PMID 24265155 · Shi et al., 2014 · Open in CIViC

Preclinical study in melanoma cell lines. Inactivity of BRAF as mediated by specific mutation (D594A, D594V or K483M) or selective pharmacological inhibition leads to MEK hyperactivation through CRAF … (full text at CIViC)

PMID 20141835 · Heidorn et al., 2010 · Open in CIViC

In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations were identified. These cell lines were resitant to MEK-Inhibition but underwent apoptosis after shRN… (full text at CIViC)

PMID 18794803 · Smalley et al., 2009 · Open in CIViC

In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations were identified. These cell lines were resitant to MEK-Inhibition but underwent apoptosis after shRN… (full text at CIViC)

PMID 18794803 · Smalley et al., 2009 · Open in CIViC

Patients were treated with a specific RAF inhibitor (dabrafenib), which improved overall survival of patients with BRAF mutations (P<0.003), compared to non-treated patients with BRAF mutations. Patie… (full text at CIViC)

PMID 21343559 · Long et al., 2011 · Open in CIViC

An inducible BRAF-V600E mouse melanoma model shows a tight correlation between activated BRAF and disease progression.

PMID 16424035 · Hoeflich et al., 2006 · Open in CIViC

Preclinical study in melanoma cell lines. Inactivity of BRAF as mediated by specific mutation (D594A, D594V or K483M) or selective pharmacological inhibition leads to MEK hyperactivation through CRAF … (full text at CIViC)

PMID 20141835 · Heidorn et al., 2010 · Open in CIViC

In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated wi… (full text at CIViC)

PMID 31580757 · Menzer et al., 2019 · Open in CIViC

In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated wi… (full text at CIViC)

PMID 31580757 · Menzer et al., 2019 · Open in CIViC

In an in vitro study, a MO-1 cell line expressing BRAF G469A demonstrated reduced sensitivity to vemurafenib treatment, similar to LND-1 cells expression BRAF wild-type. Sensitivity was determined by … (full text at CIViC)

PMID 26070258 · Porcelli et al., 2015 · Open in CIViC

In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations were identified. These cell lines were resitant to MEK-Inhibition but underwent apoptosis after shRN… (full text at CIViC)

PMID 18794803 · Smalley et al., 2009 · Open in CIViC

In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations were identified. These cell lines were resitant to MEK-Inhibition (U0126) but underwent apoptosis af… (full text at CIViC)

PMID 18794803 · Smalley et al., 2009 · Open in CIViC

In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated wi… (full text at CIViC)

PMID 31580757 · Menzer et al., 2019 · Open in CIViC

In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E or V600K (known BRAF inhibitor sensitizing mutations), MAPK pathway reactivation mechanisms were implicated in acquired r… (full text at CIViC)

PMID 24265155 · Shi et al., 2014 · Open in CIViC

In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E or V600K (known BRAF inhibitor sensitizing mutations), MAPK pathway reactivation mechanisms were implicated in acquired r… (full text at CIViC)

PMID 24265155 · Shi et al., 2014 · Open in CIViC

Preclinical study in melanoma cell lines. Inactivity of BRAF as mediated by specific mutation (D594A, D594V or K483M) or selective pharmacological inhibition leads to MEK hyperactivation through CRAF … (full text at CIViC)

PMID 20141835 · Heidorn et al., 2010 · Open in CIViC

In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated wi… (full text at CIViC)

PMID 31580757 · Menzer et al., 2019 · Open in CIViC

In a study of 197 metastatic melanoma patients, BRAF mutations were identified in 95 patients including V600E (n=70), V600K (n=19), K601E (n=1) and D594N (n=1). Patients were treated with a specific R… (full text at CIViC)

PMID 21343559 · Long et al., 2011 · Open in CIViC

In this study, the investigators followed 10 patients treated with vemurafenib, and then they collected biopsies of lesions that progressed. In one of these patients, they identified the L505H mutatio… (full text at CIViC)

PMID 25515853 · Hoogstraat et al., 2015 · Open in CIViC

Using a mutation screen in the BRAFV600E melanoma cell line A375, the L505H variant was identified as conferring resistance to vemurafenib. Analysis of the mutation in T293 cell lines found that the L… (full text at CIViC)

PMID 24112705 · Wagenaar et al., 2014 · Open in CIViC

In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated wi… (full text at CIViC)

PMID 31580757 · Menzer et al., 2019 · Open in CIViC